Experimental Overfeeding in Humans (ExpO)

May 8, 2023 updated by: Christoffer Clemmensen, University of Copenhagen

Metabolic Changes in Response to Experimental Overfeeding: A Randomized Intervention Study

The objective of this study is to determine the homeostatic mechanisms that counteract weight gain in response to experimental overfeeding.

Study Overview

Status

Completed

Conditions

Detailed Description

The homeostatic regulation of body weight implies that biological processes have evolved to protect energy stores from changes to the food environment. Accordingly, many individuals remain remarkably weight stable over years without carefully considering how much they eat or how much energy they expend, which has given rise to the theory that body weight is regulated around an individual biological 'set point'. Notably, overfeeding humans in experimentally controlled conditions, support this phenomenon, but the underlying mechanisms are unknown.

To systematically map out the components of the overfed state, the investigators will execute a 2-week randomized controlled overfeeding trial in lean and overweight individuals. The trial is preceded by a 1-week lead-in period and followed by a 2-wk controlled ad libitum study period. The comparison between lean and overweight subjects, men and women, enables the determination of whether a differential response in overfeeding-induced signals is present in relation to BMI and sex.

Study Type

Interventional

Enrollment (Actual)

24

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Christoffer Clemmensen, Assoc. Prof.
  • Phone Number: +45 22 91 63 33
  • Email: chc@sund.ku.dk

Study Locations

    • Norrebro
      • Copenhagen, Norrebro, Denmark, 2200
        • University of Copenhagen

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 38 years (Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Male or female otherwise healthy subjects
  • 20-40 years of age
  • BMI (Body mass index) between 22-30 kg/m2

Exclusion Criteria:

  • Present or previous cardiovascular disease, diabetes or thyroid-disease
  • smoking
  • more than 3 hours of planned physical activity per week

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group
Subjects in this group will have a daily energy intake equivalent of 100 % of their calculated normal daily energy intake.
Two weeks of isocaloric weight maintenance
Experimental: Overfed group
Subjects in this group will have a daily energy intake equivalent of 150 % of their calculated normal daily energy intake.
Two weeks of overfeeding

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Changes in blood protein patterns using proteomics 1 week before, during 2 weeks of overfeeding and 2 weeks after overfeeding
Time Frame: 5 weeks
Blood will be collected for proteomics at screening, at baseline, during the overfeeding intervention and during the 2-week ad libitum intervention. Samples will be measured using LCMS instrumentation consisting of a nanoelectrospray ion source to a Q Exactive HF mass spectrometer.
5 weeks
Changes in blood peptide patterns using peptidomics 1 week before, during 2 weeks of overfeeding and 2 weeks after overfeeding
Time Frame: 5 weeks
Blood will be collected for peptidomics at screening, at baseline, during the overfeeding intervention and during the 2-week ad libitum intervention. Samples will be measured using LCMS instrumentation consisting of a nanoelectrospray ion source to a Q Exactive HF mass spectrometer.
5 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Body weight
Time Frame: 5 weeks
Body weight will be measured (in kilograms) daily during the intervention using electronic Fitbit Aria 2 weight scale.
5 weeks
Fat biopsy from subcutaneous adipose tissue before and after 2 weeks of overfeeding
Time Frame: 2 weeks
Fat biopsies are obtained using Bergström biopsy needle from subcutaneous adipose tissue in the abdominal region before and after 14 days of overfeeding to assess regulated enzymes and proteins.
2 weeks
Microdialysate from subcutaneous adipose tissue before and after 2 weeks of overfeeding. The samples will be used for detection of known and unknown secreted factors
Time Frame: 2 weeks
Microdialysates are collected from micro dialysis catheters inserted into the subcutaneous adipose tissue in the abdominal region before and after 14 days of overfeeding to assess regulated enzymes and proteins.
2 weeks
Body composition in 40 subjects before and after overfeeding
Time Frame: 3 weeks
Body composition will be measured using Dual-Energy X-ray Absorptiometry (DXA) at screening (1 week before baseline), at baseline and after 14 days of overfeeding. The DXA scan enables the detection of body lean mass and body fat mass in kg.
3 weeks
Mixed meal test
Time Frame: 2 weeks
Before and after the intervention a mixed meal test will be performed
2 weeks
Changes in blood metabolome 1 week before, during 2 weeks of overfeeding and 2 weeks after overfeeding
Time Frame: 5 weeks
Blood will be collected for metabolomics at screening, at baseline, during the overfeeding intervention and during the 2-week ad libitum intervention. Metabolomics will be performed using Mass Spectrometry.
5 weeks
Activity profile of 40 subjects during the 5 week study period
Time Frame: 5 weeks
Assessment of daily physical activity levels (wearables and doubly-labelled water)
5 weeks
Detection of circulating factors
Time Frame: 5 weeks
The investigators will measure the concentration of known circulating factors from fasted blood samples and from blood samples obtained during mixed meal test, such as: Glucose, insulin, hsCRP, Hba1c, cortisol, ACTH, lactate, fatty acids, triglycerides, glycerol, catecholamines, leptin, ghrelin, adiponectin, glucagon, GDF15, FGF21, FGF19, GIP, GLP-1, PYY, CCK, interleukins, cytokines, tissue-kines, T3, T4, TSH, cholesterol.
5 weeks
Gut microbiome profile before and after 14 days of overfeeding
Time Frame: 2 weeks
Feces samples will be collected before and after 14 days of overfeeding and microbiome composition will be analyzed by using UPLC-MS/GC-MS.
2 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christoffer Clemmensen, Assoc. Prof., Assoc. prof. NNF Center for Basic Metabolic Research

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 22, 2019

Primary Completion (Actual)

January 1, 2023

Study Completion (Actual)

January 1, 2023

Study Registration Dates

First Submitted

August 8, 2019

First Submitted That Met QC Criteria

August 20, 2019

First Posted (Actual)

August 22, 2019

Study Record Updates

Last Update Posted (Actual)

May 9, 2023

Last Update Submitted That Met QC Criteria

May 8, 2023

Last Verified

May 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • ExpO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Obesity

Clinical Trials on Isocaloric diet

3
Subscribe